ConforMIS
Stage
IPO | IPOTotal Raised
$253.3MDate of IPO
7/1/2015Market Cap
0.01BStock Price
1.34Revenue
$0000About ConforMIS
ConforMIS develops and commercializes medical devices for osteoarthritis treatment and joint damage. The company's intellectual property includes patents and patent applications in the areas of imaging software, image processing, implant design, surgical techniques, instrumentation, and manufacturing, spanning knee, hip, shoulder, spine, and small joints. ConforMIS knee implants and instrumentation are designed to address all stages of osteoarthritis, the most common reason for knee replacement surgery . All devices have been cleared by the US Food and Drug Administration for marketing in the US.
Missing: ConforMIS's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: ConforMIS's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing ConforMIS
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
ConforMIS is included in 1 Expert Collection, including Medical Devices.
Medical Devices
3,501 items
https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.
ConforMIS Patents
ConforMIS has filed 211 patents.
The 3 most popular patent topics include:
- Orthopedic surgical procedures
- Implants (medicine)
- Prosthetics
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/22/2019 | 8/23/2022 | Orthopedic surgical procedures, Surgery, Surgical instruments, Implants (medicine), Prosthetics | Grant |
Application Date | 10/22/2019 |
|---|---|
Grant Date | 8/23/2022 |
Title | |
Related Topics | Orthopedic surgical procedures, Surgery, Surgical instruments, Implants (medicine), Prosthetics |
Status | Grant |
Latest ConforMIS News
Mar 8, 2023
Conformis : Investor Presentation Message : Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, projected financial position, future revenues, projected costs, projected profits, projected margins, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "grow," "improve," and "trend," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements contained in this presentation reflect our current views with respect to future events, and apply only as of the date of this presentation. We assume no obligation to update any forward-looking statements. Our business is subject to substantial risks and uncertainties, including those referenced in certain of our filings with the SEC under the heading "Risk Factors." You are encouraged to read our filings with the SEC, available at www.sec.gov, including our Annual Report or Form 10-K for the year ended December 31, 2022 filed with the SEC on March 1, 2023, as well as our Quarterly Reports on Form 10-Q and other SEC reports. You should give careful consideration to these risks and uncertainties. | 2
ConforMIS Frequently Asked Questions (FAQ)
Where is ConforMIS's headquarters?
ConforMIS's headquarters is located at 28 Crosby Drive, Bedford.
What is ConforMIS's latest funding round?
ConforMIS's latest funding round is IPO.
How much did ConforMIS raise?
ConforMIS raised a total of $253.3M.
Who are the investors of ConforMIS?
Investors of ConforMIS include AGC Equity Partners, Axel Johnson, MassDevelopment, Sovereign Fund of Kuwait, Aeris Capital and 6 more.
Who are ConforMIS's competitors?
Competitors of ConforMIS include OrthAlign, ArthroSurface, Zipline Medical, Cord Blood Registry, Stanmore Implants, Fournitures Hospitalieres, Anteis, PEAK Surgical, Osteotech, NanoPowers and 18 more.
Compare ConforMIS to Competitors
Formae, Inc. Formae is developing new approaches to cartilage replacement for osteoarthritis, using hydrogels that closely mimic the mechanical properties of hyaline cartilage. Formae's approach is in that it is minimally invasive and aims to provide for total rather than focal joint resurfacing. The company has a broad portfolio of issued and pending patents and a well-defined product and regulatory strategy. The technology can be applied to any joint, and has the potential to be implanted arthroscopically. Following the completion of ex-vivo mechanical testing that will meet a critical regulatory milestone, Formae will be seeking funds to conduct in-vivo implantation and biocompatibility testing. .
OrthAlign provides orthopedic surgeons with user-friendly and cost-effect technology for precise alignment.
DynaTherm Medical aims to develop and commercialize products for temperature management in surgical, emergency, field and industrial settings. The company's patent protected technology uses non-invasive negative pressure to access the body's natural thermoregulatory system, the AVA's (arteriovenous anastomoses).
Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.
Axis Surgical Technologies, Inc. aims to develop, manufacture, and market devices that improve quality and efficiency in spinal surgery, especially for minimally invasive surgical techniques. Based in Mountain View, California, Axis offers an integration of visualization and articulation capabilities and provides spinal surgery equipment. Axis' FDA Grant In March 2010, Axis announced that it received 510(k) clearance from the Food and Drug Administration to market its C-MOR„ Visualization Device to use in diagnostic and operative arthroscopic and endoscopic procedures. This portable tool provides visualization and illumination of an interior cavity through either a natural or surgical opening. The ergonomic lightweight device also offers practitioners the convenience of endoscopic visualization and efficient one-handed operating ability; this device can be employed in hospital outpatient departments, ambulatory surgery centers, and office surgery suites.
BioHorizons is a provider in advanced dental implant technologies and tissue regeneration products in the dental implant industry. The company, based in Birmingham, Alabama, offers a broad spectrum of products for the replacement of missing teeth including dental implants, restorative and laboratory components, soft and hard tissue biologic products, and surgical planning software. BioHorizons' unique dental implant designs are recognized for intuitive design, excellent primary stability, and high-end, esthetic outcomes through the use of BioHorizons' Laser-Lok microchannel surface technology. Laser-Lok has been shown to uniquely achieve both bone and soft tissue attachment for long-term tissue maintenance. The company has six international subsidiaries and more than 50 distributors around the world.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.